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Background
Levels of circulating tumor cells (CTCs) have been asso-
ciated with overall survival (OS) in metastatic breast [1-]
and prostate cancer []. Here we report the preliminary
associations between CTCs and OS in subjects receiving
an autologous adenoviral transduced dendritic cell (DC)
vaccine expressing human HER2 extracellular (EC) and
transmembrane (TM) domains (AdHER2ECTM) in adults
with advanced metastatic tumors with 1-3+ HER2 expres-
sion. The clinical translation of this vaccine platform was
based on animal models that documented regression and
cure of large established tumors in syngeneic BALB/c
mice using an adenoviral vector vaccine expressing rodent
HER2 ECTM mediated by the induction of polyclonal
anti-HER2 antibodies [3].
Methods
In this open label, non-randomized, two part Phase I study
(NCT01730118) CTC data are available on 18 subjects
(11 F, 7 M, median age 57 years) with HER2+ solid tumors
(8 colon cancer, 10 other cancers; IHC 1+ N=3, 2+ N=8,
3+ N=7) that are naïve to HER2-targeted therapies; 16
have received at least 2 doses of an autologous AdHER2
DC vaccine delivered at Weeks 0, 4, 8, 16 and 24. Dose
escalation occurred in cohorts of 6 patients utilizing
5x106, 10x106 and 20x 106 viable DCs per vaccine.
EpCAM+ CTCs from 10 ml of blood were detected by
integrated magnetic pre-enrichment and flow cytometric
analysis including assessment of HER2 and CXCR4
expression.
Results
In subjects with HER2 IHC 2+ or 3+ expression (N=15),
those with 11 or more HER2+ EpCAM+ CTCs per 10ml
of peripheral blood had poorer overall survival (P=0.029)
Fig 1. In non-colorectal (CRC) cancer subjects (N=11),
patients with 11 or more HER2+ EpCAM+ CTCs or
CXCR4+ EpCAM+ CTCs per 10 ml of blood had poorer
overall survival (P=0.0046 and P=0.0067, respectively). In
this same non-CRC cohort, the HER2+ EpCAM+ CTC
count showed a trend toward decrease at study Week 12
in 6 patients status post 3 doses of AdHER2 DC vaccine
(P=0.063). Patients with stable or decreasing HER2+
EpCAM+ CTCs following treatment (N=9) exhibited a
trend toward better OS (P=0.058) Fig 2.
Conclusions
In this population of patients with advanced, HER2+
metastatic solid tumors, > 11 HER2+ EpCAM+ CTCs at
baseline is associated with poorer OS in patients with
HER2 IHC 2+/3+ or non-CRC tumors. Stable or decreas-
ing HER2+ EpCAM+ CTCs following AdHER2 vaccina-
tion is associated with a preliminary trend towards
prolonged survival. These findings suggest that monitoring
HER2+ EpCAM+ CTCs warrants further investigation in
patients treated with therapeutic AdHER2 DC vaccination.
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